{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:24:22Z","timestamp":1759602262644},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,20]]},"DOI":"10.1097\/qad.0000000000000069","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T23:50:47Z","timestamp":1390866647000},"page":"577-587","source":"Crossref","is-referenced-by-count":11,"title":["Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis"],"prefix":"10.1097","volume":"28","author":[{"given":"Daniel","family":"Grint","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Mitsura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brygida","family":"Knysz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Court","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens D.","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Mocroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210130","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/432762","article-title":"Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.","volume":"192","author":"Rockstroh","year":"2005","journal-title":"J Infect Dis"},{"key":"R2-14-20210130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2893.2006.00791.x","article-title":"Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study).","volume":"14","author":"Rosenthal","year":"2007","journal-title":"J Viral Hepat"},{"key":"R3-14-20210130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-200847030-00002","article-title":"Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment.","volume":"47","author":"McCabe","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R4-14-20210130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"R5-14-20210130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.","volume":"15","author":"Martinez","year":"2001","journal-title":"AIDS"},{"key":"R6-14-20210130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/aid.2005.21.743","article-title":"Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patientphysician choice in patients with hepatitis C coinfection.","volume":"21","author":"Mocroft","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R7-14-20210130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/135965350501000704","article-title":"Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patientphysician choice in patients with hepatitis C virus coinfection.","volume":"10","author":"Mocroft","year":"2005","journal-title":"Antivir Ther"},{"key":"R8-14-20210130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/COH.0b013e32833e3ee6","article-title":"Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes.","volume":"5","author":"Peters","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"R9-14-20210130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","article-title":"Decline in the AIDS and death rates in the EuroSIDA study: an observational study.","volume":"362","author":"Mocroft","year":"2003","journal-title":"Lancet"},{"key":"R10-14-20210130","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/hiv.12033","article-title":"Stability of hepatitis C virus (HCV) RNA levels among interferon-naive HIVHCV-coinfected individuals treated with combination antiretroviral therapy.","volume":"14","author":"Grint","year":"2013","journal-title":"HIV Med"},{"key":"R11-14-20210130","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/hep.22099","article-title":"Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.","volume":"47","author":"Fontana","year":"2008","journal-title":"Hepatology"},{"key":"R12-14-20210130","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/01.qai.0000184856.31695.bf","article-title":"HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease.","volume":"40","author":"Nunes","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-14-20210130","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/jac\/dkn045","article-title":"Liver toxicity of antiretroviral combinations including atazanavirritonavir in patients co-infected with HIV and hepatitis viruses: impact of preexisting liver fibrosis.","volume":"61","author":"Pineda","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R16-14-20210130","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jac\/dkl074","article-title":"Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.","volume":"57","author":"Pineda","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R17-14-20210130","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/135965350601100701","article-title":"Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.","volume":"11","author":"Macias","year":"2006","journal-title":"Antivir Ther"},{"key":"R19-14-20210130","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/COH.0b013e32834bd365","article-title":"HIVhepatitis C coinfection natural history and disease progression.","volume":"6","author":"Hernandez","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"R20-14-20210130","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.","volume":"22","author":"Thein","year":"2008","journal-title":"AIDS"},{"key":"R21-14-20210130","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23679","article-title":"Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIVhepatitis C virus-induced liver fibrosis.","volume":"52","author":"Tuyama","year":"2010","journal-title":"Hepatology"},{"key":"R22-14-20210130","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.","volume":"40","author":"Aranzabal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R23-14-20210130","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/jac\/dkq320","article-title":"Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.","volume":"65","author":"Dominguez","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R24-14-20210130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1086\/317644","article-title":"Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus.","volume":"183","author":"Puoti","year":"2001","journal-title":"J Infect Dis"},{"key":"R25-14-20210130","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by nonnucleoside reverse transcriptase inhibitors.","volume":"59","author":"Rivero","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R26-14-20210130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"R27-14-20210130","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.","volume":"196","author":"Labarga","year":"2007","journal-title":"J Infect Dis"},{"key":"R29-14-20210130","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2893.2012.01596.x","article-title":"Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.","volume":"19","author":"Suarez-Zarracina","year":"2012","journal-title":"J Viral Hepat"},{"key":"R30-14-20210130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.qai.0000221683.44940.62","article-title":"Severe liver disease associated with prolonged exposure to antiretroviral drugs.","volume":"42","author":"Maida","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-14-20210130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1086\/505495","article-title":"Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.","volume":"43","author":"McGovern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R32-14-20210130","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.","volume":"44","author":"Nunez","year":"2006","journal-title":"J Hepatol"},{"key":"R33-14-20210130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIVHCV coinfection and liver cirrhosis during interferon-based therapy.","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"R34-14-20210130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAI.0b013e318040b2b6","article-title":"Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role.","volume":"45","author":"Bani-Sadr","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R36-14-20210130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3851\/IMP1708","article-title":"Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV.","volume":"16","author":"Carton","year":"2011","journal-title":"Antivir Ther"},{"key":"R37-14-20210130","doi-asserted-by":"crossref","first-page":"e40245","DOI":"10.1371\/journal.pone.0040245","article-title":"Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults.","volume":"7","author":"Mocroft","year":"2012","journal-title":"Plos One"},{"key":"R39-14-20210130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit043","article-title":"Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D: A: D study.","volume":"207","author":"Ryom","year":"2013","journal-title":"J Infect Dis"},{"key":"R40-14-20210130","first-page":"36","article-title":"Hepatotoxicity of antiretroviral therapy.","volume":"5","author":"Kontorinis","year":"2003","journal-title":"AIDS Rev"},{"key":"R41-14-20210130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2796.2005.01564.x","article-title":"Mechanisms by which food intake elevates circulating levels of hyaluronan in humans.","volume":"258","author":"Fraser","year":"2005","journal-title":"J Int Med"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0000000000000069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T02:46:09Z","timestamp":1688957169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201402200-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0000000000000069","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}